BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

143 related articles for article (PubMed ID: 22529031)

  • 1. Characterization of a new human melanoma cell line with CD133 expression.
    Gil-Benso R; Monteagudo C; Cerdá-Nicolás M; Callaghan RC; Pinto S; Martínez-Romero A; Pellín-Carcelén A; San-Miguel T; Cigudosa JC; López-Ginés C
    Hum Cell; 2012 Jun; 25(2):61-7. PubMed ID: 22529031
    [TBL] [Abstract][Full Text] [Related]  

  • 2. CD133 and ABCB5 as stem cell markers on sentinel lymph node from melanoma patients.
    Gazzaniga P; Cigna E; Panasiti V; Devirgiliis V; Bottoni U; Vincenzi B; Nicolazzo C; Petracca A; Gradilone A
    Eur J Surg Oncol; 2010 Dec; 36(12):1211-4. PubMed ID: 20573479
    [No Abstract]   [Full Text] [Related]  

  • 3. BRAF, KIT and NRAS mutations and expression of c-KIT, phosphorylated extracellular signal-regulated kinase and phosphorylated AKT in Japanese melanoma patients.
    Oyama S; Funasaka Y; Watanabe A; Takizawa T; Kawana S; Saeki H
    J Dermatol; 2015 May; 42(5):477-84. PubMed ID: 25766129
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Phenotyping of human melanoma cells reveals a unique composition of receptor targets and a subpopulation co-expressing ErbB4, EPO-R and NGF-R.
    Mirkina I; Hadzijusufovic E; Krepler C; Mikula M; Mechtcheriakova D; Strommer S; Stella A; Jensen-Jarolim E; Höller C; Wacheck V; Pehamberger H; Valent P
    PLoS One; 2014; 9(1):e84417. PubMed ID: 24489649
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Metastatic Malignant Melanoma With Complete Loss of Differentiation Markers (Undifferentiated/Dedifferentiated Melanoma): Analysis of 14 Patients Emphasizing Phenotypic Plasticity and the Value of Molecular Testing as Surrogate Diagnostic Marker.
    Agaimy A; Specht K; Stoehr R; Lorey T; Märkl B; Niedobitek G; Straub M; Hager T; Reis AC; Schilling B; Schneider-Stock R; Hartmann A; Mentzel T
    Am J Surg Pathol; 2016 Feb; 40(2):181-91. PubMed ID: 26448190
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Molecular characterization of human cutaneous melanoma-derived cell lines.
    Ogbah Z; Puig-Butille JA; Simonetta F; Badenas C; Cervera R; Milá J; Benitez D; Malvehy J; Vilella R; Puig S
    Anticancer Res; 2012 Apr; 32(4):1245-51. PubMed ID: 22493355
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Melanoma stem cells: the dark seed of melanoma.
    Zabierowski SE; Herlyn M
    J Clin Oncol; 2008 Jun; 26(17):2890-4. PubMed ID: 18539969
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Characterization of genetic alterations in primary human melanomas carrying BRAF or NRAS mutation].
    Lázár V
    Magy Onkol; 2013 Jun; 57(2):96-9. PubMed ID: 23795354
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Investigation of CD133 as putative marker of tumor-initiating cell in laryngeal carcinoma].
    Wei XD; Zhou L; Cheng L; Tian J
    Zhonghua Er Bi Yan Hou Tou Jing Wai Ke Za Zhi; 2007 Sep; 42(9):692-6. PubMed ID: 18051573
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Prevalence of BRAF, NRAS and c-KIT mutations in Slovenian patients with advanced melanoma.
    Moltara ME; Novakovic S; Boc M; Bucic M; Rebersek M; Zadnik V; Ocvirk J
    Radiol Oncol; 2018 Apr; 52(3):289-295. PubMed ID: 30210039
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The identification of patient-specific mutations reveals dual pathway activation in most patients with melanoma and activated receptor tyrosine kinases in BRAF/NRAS wild-type melanomas.
    Appenzeller S; Gesierich A; Thiem A; Hufnagel A; Jessen C; Kneitz H; Regensburger M; Schmidt C; Zirkenbach V; Bischler T; Schilling B; Siedel C; Goebeler ME; Houben R; Schrama D; Gehrig A; Rost S; Maurus K; Bargou R; Rosenwald A; Schartl M; Goebeler M; Meierjohann S
    Cancer; 2019 Feb; 125(4):586-600. PubMed ID: 30561760
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Mutation analysis of BRAF and KIT in circulating melanoma cells at the single cell level.
    Sakaizawa K; Goto Y; Kiniwa Y; Uchiyama A; Harada K; Shimada S; Saida T; Ferrone S; Takata M; Uhara H; Okuyama R
    Br J Cancer; 2012 Feb; 106(5):939-46. PubMed ID: 22281663
    [TBL] [Abstract][Full Text] [Related]  

  • 13. BRAF, NRAS and KIT sequencing analysis of spindle cell melanoma.
    Kim J; Lazar AJ; Davies MA; Homsi J; Papadopoulos NE; Hwu WJ; Bedikian AY; Woodman SE; Patel SP; Hwu P; Kim KB
    J Cutan Pathol; 2012 Sep; 39(9):821-5. PubMed ID: 22809251
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Clinicopathological characteristics and mutation profiling in primary cutaneous melanoma.
    Yaman B; Akalin T; Kandiloğlu G
    Am J Dermatopathol; 2015 May; 37(5):389-97. PubMed ID: 25357015
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Clonal dominance of CD133+ subset population as risk factor in tumor progression and disease recurrence of human cutaneous melanoma.
    Sharma BK; Manglik V; O'Connell M; Weeraratna A; McCarron EC; Broussard JN; Divito KA; Simbulan-Rosenthal CM; Rosenthal DS; Zapas JL
    Int J Oncol; 2012 Nov; 41(5):1570-6. PubMed ID: 22922842
    [TBL] [Abstract][Full Text] [Related]  

  • 16.
    Ponti G; Manfredini M; Greco S; Pellacani G; Depenni R; Tomasi A; Maccaferri M; Cascinu S
    Anticancer Res; 2017 Dec; 37(12):7043-7048. PubMed ID: 29187493
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Adhesion control of cyclin D1 and p27Kip1 levels is deregulated in melanoma cells through BRAF-MEK-ERK signaling.
    Bhatt KV; Spofford LS; Aram G; McMullen M; Pumiglia K; Aplin AE
    Oncogene; 2005 May; 24(21):3459-71. PubMed ID: 15735667
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Assessment of clinical parameters associated with mutational status in metastatic malignant melanoma: a single-centre investigation of 141 patients.
    Schlaak M; Bajah A; Podewski T; Kreuzberg N; von Bartenwerffer W; Wardelmann E; Merkelbach-Bruse S; Büttner R; Mauch C; Kurschat P
    Br J Dermatol; 2013 Apr; 168(4):708-16. PubMed ID: 23528057
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pharmacodynamic characterization of the efficacy signals due to selective BRAF inhibition with PLX4032 in malignant melanoma.
    Tap WD; Gong KW; Dering J; Tseng Y; Ginther C; Pauletti G; Glaspy JA; Essner R; Bollag G; Hirth P; Zhang C; Slamon DJ
    Neoplasia; 2010 Aug; 12(8):637-49. PubMed ID: 20689758
    [TBL] [Abstract][Full Text] [Related]  

  • 20. CD133+ melanoma subpopulations contribute to perivascular niche morphogenesis and tumorigenicity through vasculogenic mimicry.
    Lai CY; Schwartz BE; Hsu MY
    Cancer Res; 2012 Oct; 72(19):5111-8. PubMed ID: 22865455
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.